On 3 July 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) approved the semaglutide injection (brand name Wegovy) for the treatment of metabolic‑associated steatohepatitis (MASH) in adults with moderate‑to‑advanced liver fibrosis. Semaglutide, already authorised for weight management and cardiovascular risk reduction, will be prescribed once weekly with a stepwise dose increase, reaching a maintenance dose of 2.4 mg, and up to 7.2 mg for patients with BMI over 30. The approval is conditional; further confirmatory evidence is required before a full marketing authorisation can be issued, and the MHRA will review new data annually. NHS access will depend on a decision from NICE, which is currently evaluating the drug’s clinical and cost‑effectiveness. The most common side effects are gastrointestinal, including nausea, diarrhoea, constipation and vomiting.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.